ReviewIndian journal of gastroenterology : official journal of the Indian Society of Gastroenterology2024
Gut bacteriome in inflammatory bowel disease: An update on recent advances.
Review in Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 27 citations in OpenAlex.
- ProbioticMicrobiology spectrum · 2026Article
- Postbiotic Nagqu4580 Attenuates Ulcerative Colitis and Suppresses Ferroptosis in Association with the Microbiota-Tryptophan-AhR/Nrf2 Axis.Nutrients · 2026Article
- Plant-Derived Foods and Medicines as Modulators of the Gut Microbiome: Molecular Interactions and Implications for Disease and Therapy.Molecules (Basel, Switzerland) · 2026Review
- From dysbacteriosis to ecological remodeling: A new breakthrough in microbial treatment of inflammatory bowel disease.iScience · 2026Review
- Lactobacillus reuteri SKLAN202402ZF inhibited by early-life lincomycin exposure alleviate intestinal damage and inflammation sensitivity.Microbiome · 2026Article
- Gut microbiota in genetic diseases: from Mendelian disorders to complex traits.Frontiers in immunology · 2026Review
- Nutrigenomics meets multi-omics: integrating genetic, metabolic, and microbiome data for personalized nutrition strategies.Genes & nutrition · 2025Review
- Medicinal Plants for a Healthy Gut Microbiome: Scientific Insights into Modern Herbal Applications.International journal of molecular sciences · 2025Review
- Gut microbiome in early life and bone health outcomes at age 6: a Danish mother-child cohort study.Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2025Article
- The Gut Microbiome of the Asiatic Toad (Ecology and evolution · 2025Article
- Gut Microbiota Serves as a Crucial Independent Biomarker in Inflammatory Bowel Disease (IBD).International journal of molecular sciences · 2025Review
- Immune dysregulation in ulcerative colitis: pathogenic mechanisms and therapeutic strategies of traditional Chinese medicine.Frontiers in cell and developmental biology · 2025Review
- Inorganic dietary nanoparticles in intestinal barrier function of inflammatory bowel disease: allies or adversaries?Frontiers in immunology · 2025Review
- Apigenin protects ischemic stroke by regulating intestinal microbiota homeostasis, regulates brain metabolic profile.Frontiers in pharmacology · 2025Article
- Deciphering the Interplay Among Inflammatory Bowel Disease, Gut Microbiota, and Inflammatory Biomarkers in the Risk of Colorectal Cancer.Mediators of inflammation · 2025Article
- The Role of Prebiotics in Modulating Gut Microbiota: Implications for Human Health.International journal of molecular sciences · 2024Review
- Traditional Chinese medicine for functional gastrointestinal disorders and inflammatory bowel disease: narrative review of the evidence and potential mechanisms involving the brain-gut axis.Frontiers in pharmacology · 2024Review
- Microbiome and Mucosal Immunity in the Intestinal Tract.In vivo (Athens, Greece)Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Inflammatory bowel diseases (IBD) are chronic inflammatory gut disorders, majorly classified as ulcerative colitis and Crohn's disease. The complex, multifactorial etiopathogenesis of IBD involves genetic predisposition, environmental cues, aberrant mucosal immune response and a disturbed gut microbiota. Epidemiological trends, studies in gnotobiotic mice models and genome-wide association studies, identifying genes involved in microbial handling, together mount evidence in support of the gut microbiota playing a pivotal role in IBD pathogenesis. Both Crohn's disease and ulcerative colitis are characterized by severe dysbiosis of the gut microbiome, marked by an expansion of detrimental taxa and concomitant depletion of beneficial members. IBD is characterized by reduction in abundances of bacterial genera involved in production of short-chain fatty acids, bio-transformations of bile acids and synthesis of indole-based tryptophan compounds such as Faecalibacterium, Ruminococcus, Coprococcus, Dorea, Parabacteroides, Eubacterium, Oscillibacter and Prevotella and elevation in members of phyla Proteobacteria and Actinobacteria. This imbalance not only results in exaggerated immune signaling towards the microbial antigens, but also results in an altered metabolomic milieu that triggers additional inflammatory cascades. The present review provides insights into the bacterial dysbiosis observed across different intestinal sites and their metabolomic imprints participating in IBD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.